Compare Stocks: TWST, GPCR, and ARDX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARDX Ardelyx	$3.42 +0.9%	$4.00	$3.31 ▼ $8.40	$844.75M	0.7	3.96 million shs	4.41 million shs
GPCR Structure Therapeutics	$31.27 -4.3%	$45.54	$25.59 ▼ $94.90	$2.28B	-1.45	1.30 million shs	2.18 million shs
TWST Twist Bioscience	$193.24 +3.8%	$132.52	$23.30 ▼ $197.19	$11.67B	2.22	2.03 million shs	3.25 million shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARDX Ardelyx	+0.88%	-1.72%	-9.52%	-35.10%	-37.93%
GPCR Structure Therapeutics	-4.34%	-13.02%	-31.89%	-41.50%	+11.68%
TWST Twist Bioscience	+3.82%	+21.92%	+39.02%	+94.72%	+586.71%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARDX Ardelyx	$3.42 +0.9%	$4.00	$3.31 ▼ $8.40	$844.75M	0.7	3.96 million shs	4.41 million shs
GPCR Structure Therapeutics	$31.27 -4.3%	$45.54	$25.59 ▼ $94.90	$2.28B	-1.45	1.30 million shs	2.18 million shs
TWST Twist Bioscience	$193.24 +3.8%	$132.52	$23.30 ▼ $197.19	$11.67B	2.22	2.03 million shs	3.25 million shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARDX Ardelyx	+0.88%	-1.72%	-9.52%	-35.10%	-37.93%
GPCR Structure Therapeutics	-4.34%	-13.02%	-31.89%	-41.50%	+11.68%
TWST Twist Bioscience	+3.82%	+21.92%	+39.02%	+94.72%	+586.71%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARDX Ardelyx	2.75	Moderate Buy	$13.90	306.43% Upside
GPCR Structure Therapeutics	2.82	Moderate Buy	$110.91	254.68% Upside
TWST Twist Bioscience	2.50	Moderate Buy	$105.73	-45.29% Downside

Current Analyst Ratings Breakdown

Latest TWST, GPCR, and ARDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/29/2026	TWST Twist Bioscience	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$160.00 ➝ $190.00
9/25/2026	ARDX Ardelyx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/21/2026	TWST Twist Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/18/2026	GPCR Structure Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/18/2026	TWST Twist Bioscience	BWS Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell	$45.00
9/17/2026	TWST Twist Bioscience	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$120.00 ➝ $160.00
9/9/2026	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/9/2026	GPCR Structure Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$110.00
9/9/2026	TWST Twist Bioscience	BWS Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell	$45.00
9/9/2026	TWST Twist Bioscience	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$144.00
8/24/2026	TWST Twist Bioscience	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 10/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARDX Ardelyx	$407.32M	2.09	N/A	N/A	$0.69 per share	4.96
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$24.99 per share	N/A
TWST Twist Bioscience	$376.57M	32.18	N/A	N/A	$7.84 per share	24.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARDX Ardelyx	-$61.60M	-$0.22	N/A	14.25	N/A	-12.35%	-36.00%	-10.77%	10/29/2026 (Estimated)
GPCR Structure Therapeutics	-$141.20M	-$1.00	N/A	N/A	N/A	N/A	-25.56%	-24.31%	11/5/2026 (Estimated)
TWST Twist Bioscience	-$77.67M	-$2.22	N/A	N/A	N/A	-31.66%	-28.64%	-19.94%	11/13/2026 (Estimated)

Latest TWST, GPCR, and ARDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/29/2026	Q3 2026	ARDX Ardelyx	-$0.0139	N/A	N/A	N/A	$129.22 million	N/A
8/6/2026	Q2 2026	ARDX Ardelyx	-$0.05	-$0.07	-$0.02	-$0.07	$121.04 million	$120.88 million
8/6/2026	Q2 2026	GPCR Structure Therapeutics	-$0.39	-$0.49	-$0.10	-$0.49	N/A	N/A
8/3/2026	Q3 2026	TWST Twist Bioscience	-$0.5063	-$0.56	-$0.0538	-$0.56	$114.55 million	$118.38 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A
TWST Twist Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARDX Ardelyx	1.69	3.34	3.15
GPCR Structure Therapeutics	N/A	20.75	20.75
TWST Twist Bioscience	0.03	2.67	2.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARDX Ardelyx	58.92%
GPCR Structure Therapeutics	91.78%
TWST Twist Bioscience	N/A

Insider Ownership

Company	Insider Ownership
ARDX Ardelyx	5.30%
GPCR Structure Therapeutics	5.50%
TWST Twist Bioscience	3.08%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARDX Ardelyx	489	249.19 million	235.98 million	Optionable
GPCR Structure Therapeutics	281	69.62 million	65.79 million	Optionable
TWST Twist Bioscience	979	62.71 million	60.78 million	Optionable

TWST, GPCR, and ARDX Headlines

Recent News About These Companies

The Top HealthTech Questions Landing on Our Desks

September 30 at 7:06 AM | etftrends.comE

Twist Bioscience Corporation (NASDAQ:TWST) Stock Rated "Moderate Buy" by Sell-Side Brokerages

September 30 at 3:14 AM | americanbankingnews.com

Twist Bioscience (NASDAQ:TWST) Hits New 1-Year High - What's Next?

September 29 at 2:59 AM | marketbeat.com

Twist Bioscience: Don't Confuse A Short Squeeze With An AI Revolution

September 28 at 9:13 PM | seekingalpha.com

Alpha Teknova (NASDAQ:TKNO) versus Twist Bioscience (NASDAQ:TWST) Critical Comparison

September 28 at 6:28 AM | americanbankingnews.com

What Needs To Be True To Buy Twist Bioscience Stock Now?

September 26, 2026 | finance.yahoo.com

Twist Bioscience (NASDAQ:TWST) CEO Emily Leproust Sells 5,203 Shares of Stock

September 26, 2026 | americanbankingnews.com

Twist Bioscience (NASDAQ:TWST) CEO Emily Leproust Sells 5,203 Shares of Company Stock

September 26, 2026 | insidertrades.com

Insider Selling: Twist Bioscience (NASDAQ:TWST) CEO Sells 5,203 Shares of Company Stock

September 25, 2026 | marketbeat.com

Twist Bioscience Corporation (NASDAQ:TWST) Stock Has Consensus Price Target of $103.00 According to Brokerages

September 25, 2026 | marketbeat.com

Twist Bioscience (NASDAQ:TWST) Trading 8.9% Higher - Here's Why

September 24, 2026 | marketbeat.com

Twist Bioscience (NASDAQ:TWST) Insider Dennis Cho Sells 348 Shares of Stock

September 24, 2026 | americanbankingnews.com

Twist Bioscience (NASDAQ:TWST) SVP Paula Green Sells 294 Shares of Stock

September 24, 2026 | insidertrades.com

Corient Private Wealth LP Takes $2.23 Million Position in Twist Bioscience Corporation $TWST

September 24, 2026 | marketbeat.com

Paula Green Sells 294 Shares of Twist Bioscience (NASDAQ:TWST) Stock

September 23, 2026 | marketbeat.com

Insider Selling: Twist Bioscience (NASDAQ:TWST) Insider Sells $57,590.52 in Stock

September 23, 2026 | marketbeat.com

Emily Leproust Sells 1,687 Shares of Twist Bioscience (NASDAQ:TWST) Stock

September 23, 2026 | marketbeat.com

Twist Bioscience Slides as Recent Rally Cools and CEO Sale Filing Weighs on Sentiment

September 23, 2026 | quiverquant.comQ

Twist Bioscience (NASDAQ:TWST) Hits New 12-Month High - Here's Why

September 23, 2026 | americanbankingnews.com

Twist Bioscience (NASDAQ:TWST) Sets New 1-Year High - Should You Buy?

September 23, 2026 | marketbeat.com

3 Analysts, 3 Trades to Make Today

September 22, 2026 | investorplace.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TWST, GPCR, and ARDX Company Descriptions

Ardelyx NASDAQ:ARDX

$3.42 +0.03 (+0.88%)

Closing price 09/30/2026 04:00 PM Eastern

Extended Trading

$3.40 -0.02 (-0.44%)

As of 09/30/2026 07:30 PM Eastern

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Structure Therapeutics NASDAQ:GPCR

$31.27 -1.42 (-4.34%)

Closing price 09/30/2026 04:00 PM Eastern

Extended Trading

$31.22 -0.04 (-0.14%)

As of 09/30/2026 07:47 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Twist Bioscience NASDAQ:TWST

$193.24 +7.11 (+3.82%)

Closing price 09/30/2026 04:00 PM Eastern

Extended Trading

$195.56 +2.32 (+1.20%)

As of 09/30/2026 07:59 PM Eastern

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TWST, GPCR, and ARDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TWST, GPCR, and ARDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TWST, GPCR, and ARDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TWST, GPCR, and ARDX Company Descriptions

Ardelyx NASDAQ:ARDX

Structure Therapeutics NASDAQ:GPCR

Twist Bioscience NASDAQ:TWST

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TWST, GPCR, and ARDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TWST, GPCR, and ARDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TWST, GPCR, and ARDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TWST, GPCR, and ARDX Company Descriptions

Ardelyx NASDAQ:ARDX

Structure Therapeutics NASDAQ:GPCR

Twist Bioscience NASDAQ:TWST

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools